Phase I Trial of the Combination of Flavopiridol and Imatinib Mesylate in Patients with Bcr-Abl(+) Hematological Malignancies

PURPOSE: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bose, Prithviraj, Perkins, Edward B, Honeycut, Connie, Wellons, Martha D, Stefan, Tammy, Jacobberger, James W, Kontopodis, Emmanouil, Beumer, Jan H, Egorin, Merrill J, Imamura, Chiyo K, Figg, W Douglas, Karp, Judith E, Koc, Omer N, Cooper, Brenda W, Luger, Selina M, Colevas, A Dimitrios, Roberts, John D, Grant, Steven
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365614/
https://ncbi.nlm.nih.gov/pubmed/22349810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1839-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares